SPN-812 is a selective norepinephrine reuptake inhibitor, which, according to Supernus, could be more effective and have a better side effect profile than other non-stimulant treatments for ADHD due to its different pharmacological profile.
The study also demonstrated statistically significant median reduction versus placebo in both investigator-rated and patient-rated ADHD symptom scores.
The randomised, double-blind, placebo-controlled trial evaluated 53 adults with a current diagnosis of ADHD.
The primary endpoints were safety and tolerability, while the secondary endpoints included the efficacy of SPN-812, and the effectiveness of SPN-812 when compared to placebo.